HIGHLIGHTS
- who: Lukas Weiss from the (UNIVERSITY) have published the paper: short review, in the Journal: (JOURNAL) of 28/04/2022
SUMMARY
ESMO 2021-highlights in colorectal cancer in heavily pretreated KRAS G12C-mutated metastatic CRC. This combination is based on the rationale that EGFR signaling has been identified as the dominant mechanism of CRC resistance to KRAS G12C inhibitors. Based on these results, adagrasib and cetuximab is compared to standard chemotherapy plus/minus antiangiogenic agent in the KRYSTAL-10 trial, a phase 3 randomized trial in patients with KRAS G12C mutated metastatic CRC . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.